P114 (0041) RESULTS OF MINI-BEAM AS SECOND SALVAGE CHEMOTHERAPY AFTER DHAP BASED CHEMOTHERAPY FOR RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

P114 (0041) RESULTS OF MINI-BEAM AS SECOND SALVAGE CHEMOTHERAPY AFTER DHAP BASED CHEMOTHERAPY FOR RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Bibliographic Details
Format:	Article
Language:	English
Published:	Wiley 2018-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000547959.28876.b4

Similar Items

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
by: Harsh Shah, et al.
Published: (2022-10-01)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
by: D. Ermann, et al.
Published: (2022-06-01)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
by: Kmira Zahra, et al.
Published: (2023-08-01)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
by: Chiara Rusconi, et al.
Published: (2023-08-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
by: Xianggui Yuan, et al.
Published: (2022-11-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens
by: Jacopo Mariotti, et al.
Published: (2024-01-01)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
by: Bogdan Popescu, et al.
Published: (2019-12-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
by: Radhika Takiar, et al.
Published: (2022-07-01)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
by: Michael P. Randall, et al.
Published: (2023-09-01)

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
by: Yujie Zhang, et al.
Published: (2022-07-01)

Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
by: Elisa Lucchini, et al.
Published: (2021-06-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?
by: Selma Addou, et al.
Published: (2021-10-01)

S221: BORTEZOMIB TO R-DHAP COMPARED TO R-DHAP IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE TO STEM CELL TRANPLANTATION: FINAL RESULTS OF PHASE II RANDOMIZED FIL-VERAL12
by: A. Chiappella, et al.
Published: (2022-06-01)

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
by: Pattamaporn Boonlerd, et al.
Published: (2023-12-01)

Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study
by: Yu Yagi, et al.
Published: (2023-09-01)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
by: Simonetta Viviani, et al.
Published: (2022-10-01)

P104 (0004) NIVOLUMAB IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA: EXPERIENCE WITH TEN PATIENTS
Published: (2018-10-01)

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma
by: Walter Hanel, et al.
Published: (2023-02-01)

Unusually swift response of relapsed Burkitt leukemia to R‐DHAP
by: Dennis Christoph Harrer, et al.
Published: (2022-08-01)

P113 (0040) PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN IN FIRST REFRACTORY/RELAPSED CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED BY CHEMOTHERAPY (ICE) BEFORE AUTOLOGOUS TRANSPLANTATION
Published: (2018-10-01)

P134 (0156) INDUCTION THERAPY WITH EVEROLIMUS IN COMBINATION WITH DHAP (DEXAMETHASONE, HIGH-DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL (HD-R3I)
Published: (2018-10-01)

PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.
by: Celia Martinez, et al.
Published: (2023-08-01)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
by: Theodoros P. Vassilakopoulos, et al.
Published: (2022-10-01)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
by: Nesreen Ali, et al.
Published: (2023-08-01)

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
by: Yanfei Liu, et al.
Published: (2024-03-01)

PCV salvage chemotherapy for recurrent primary CNS lymphoma.
by: Herrlinger, U, et al.
Published: (2000)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01)

P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL
by: Y. Xie, et al.
Published: (2022-06-01)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
by: Simon Hallam
Published: (2018-08-01)

Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study
by: Simon J. Bulley, et al.
Published: (2022-11-01)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
by: Anastasia Semenova, et al.
Published: (2023-08-01)

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
by: Weiping Liu, et al.
Published: (2023-09-01)